Naloxegol 25 MG Oral Tablet [Movantik] + Placebo Oral Tablet

Phase 2Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Gastroparesis

Conditions

Gastroparesis, Opioid Use

Trial Timeline

Dec 29, 2016 → Sep 30, 2019

NCT ID

NCT03036891

About Naloxegol 25 MG Oral Tablet [Movantik] + Placebo Oral Tablet

Naloxegol 25 MG Oral Tablet [Movantik] + Placebo Oral Tablet is a phase 2 stage product being developed by AstraZeneca for Gastroparesis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03036891. Target conditions include Gastroparesis, Opioid Use.

What happened to similar drugs?

6 of 8 similar drugs in Gastroparesis were approved

Approved (6) Terminated (4) Active (2)

✅tadalafilEli LillyApproved

✅Mosapride + domperidoneSumitomo PharmaApproved

✅Cisapride + PlaceboJohnson & JohnsonApproved

✅TegaserodNovartisApproved

✅Immediate-release omeprazole + Delayed-release omeprazoleBausch HealthApproved

🔄TradipitantVanda PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03036891	Phase 2	Withdrawn	Dec 29, 2016	Sep 30, 2019	Gastroparesis

Competing Products

19 competing products in Gastroparesis

See all competitors

Product	Company	Stage	Hype Score
tadalafil + tadalafil + placebo	Eli Lilly	Phase 2	35
Granisetron	Kyowa Kirin	Phase 2	27
tadalafil	Eli Lilly	Approved	35
Mosapride + domperidone	Sumitomo Pharma	Approved	39
Cisapride + Placebo	Johnson & Johnson	Approved	35
Cisapride + Placebo	Johnson & Johnson	Approved	35
Sitagliptin + Placebo	Merck	Phase 1	29
Tegaserod	Novartis	Approved	35
Reglan ODT	UCB	Pre-clinical	26
Hemin + Albumin	Recordati	Phase 2	32
CNSA-001 + Placebo	PTC Therapeutics	Phase 2	32
Immediate-release omeprazole + Delayed-release omeprazole	Bausch Health	Approved	37
Velusetrag + Placebo	Theravance Biopharma	Phase 2	29
velusetrag dose 1 + velusetrag dose 2 + velusetrag dose 3 + placebo	Theravance Biopharma	Phase 2	29
IW-9179 + Matching Placebo	Ironwood Pharmaceuticals	Phase 2	29
VLY-686 (Tradipitant)	Vanda Pharmaceuticals	Phase 2	25
Tradipitant	Vanda Pharmaceuticals	Phase 3	37
Tradipitant	Vanda Pharmaceuticals	Pre-clinical	20
Tradipitant + Placebo + Open Label Tradipitant	Vanda Pharmaceuticals	Phase 3	30